Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nicholas Reed

Showing results (51-60 of 69) with videos related to

Pageof 7
Sort By:
The Lancet. Oncology|October 18, 2015
Cediranib combined with carboplatin and paclitaxel in patients with metastatic or recurrent cervical cancer (CIRCCa): a randomised, double-blind, placebo-controlled phase 2 trialR Paul Symonds, Charlie Gourley, Susan Davidson, et al.
Neuroendocrinology|September 21, 2018
Unmet Needs in Appendiceal Neuroendocrine NeoplasmsChristos Toumpanakis, Nicola Fazio, Eva Tiensuu Janson, et al.
BMJ Open|February 8, 2020
NET-02 trial protocol: a multicentre, randomised, parallel group, open-label, phase II, single-stage selection trial of liposomal irinotecan (nal-IRI) and 5-fluorouracil (5-FU)/folinic acid or docetaxel as second-line therapy in patients with progressive poorly differentiated extrapulmonary neuroendocrine carcinoma (NEC)Zoe Craig, Jayne Swain, Emma Batman, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|November 14, 2007
ESGO statement on cervical cancer vaccinationIgnace Vergote, Ate G J van der Zee, Vesna Kesic, et al.
The ISME Journal|July 21, 2025
Absolute abundance unveils Basidiobolus as a cross-domain bridge indirectly bolstering gut microbiome homeostasisMitra Ghotbi, Jason E Stajich, Jason W Dallas, et al.
European Journal of Cancer (Oxford, England : 1990)|July 13, 2010
Sequential adjuvant chemotherapy and radiotherapy in endometrial cancer--results from two randomised studiesThomas Hogberg, Mauro Signorelli, Carlos Freire de Oliveira, et al.
The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences|August 20, 2025
Mortality and hospitalization among older caregivers: Results from the Atherosclerosis Risk in Communities StudyShoshana H Ballew, Emmanuel E Garcia Morales, Wuyang Zhang, et al.
Alzheimer'S & Dementia (New York, N. Y.)|October 26, 2017
A randomized feasibility pilot trial of hearing treatment for reducing cognitive decline: Results from the Aging and Cognitive Health Evaluation in Elders Pilot StudyJennifer A Deal, Marilyn S Albert, Michelle Arnold, et al.
The Oncologist|December 16, 2017
Phase II Study of BEZ235 versus Everolimus in Patients with Mammalian Target of Rapamycin Inhibitor-Naïve Advanced Pancreatic Neuroendocrine TumorsRamon Salazar, Rocio Garcia-Carbonero, Steven K Libutti, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 2, 2013
Randomized multicenter phase II trial comparing two schedules of etirinotecan pegol (NKTR-102) in women with recurrent platinum-resistant/refractory epithelial ovarian cancerIgnace B Vergote, Agustin Garcia, John Micha, et al.
Pageof 7

Showing results (51-60 of 69) with videos related to

Sort By:
Pageof 7
The Lancet. Oncology|October 18, 2015
Cediranib combined with carboplatin and paclitaxel in patients with metastatic or recurrent cervical cancer (CIRCCa): a randomised, double-blind, placebo-controlled phase 2 trialR Paul Symonds, Charlie Gourley, Susan Davidson, et al.
Neuroendocrinology|September 21, 2018
Unmet Needs in Appendiceal Neuroendocrine NeoplasmsChristos Toumpanakis, Nicola Fazio, Eva Tiensuu Janson, et al.
BMJ Open|February 8, 2020
NET-02 trial protocol: a multicentre, randomised, parallel group, open-label, phase II, single-stage selection trial of liposomal irinotecan (nal-IRI) and 5-fluorouracil (5-FU)/folinic acid or docetaxel as second-line therapy in patients with progressive poorly differentiated extrapulmonary neuroendocrine carcinoma (NEC)Zoe Craig, Jayne Swain, Emma Batman, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|November 14, 2007
ESGO statement on cervical cancer vaccinationIgnace Vergote, Ate G J van der Zee, Vesna Kesic, et al.
The ISME Journal|July 21, 2025
Absolute abundance unveils Basidiobolus as a cross-domain bridge indirectly bolstering gut microbiome homeostasisMitra Ghotbi, Jason E Stajich, Jason W Dallas, et al.
European Journal of Cancer (Oxford, England : 1990)|July 13, 2010
Sequential adjuvant chemotherapy and radiotherapy in endometrial cancer--results from two randomised studiesThomas Hogberg, Mauro Signorelli, Carlos Freire de Oliveira, et al.
The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences|August 20, 2025
Mortality and hospitalization among older caregivers: Results from the Atherosclerosis Risk in Communities StudyShoshana H Ballew, Emmanuel E Garcia Morales, Wuyang Zhang, et al.
Alzheimer'S & Dementia (New York, N. Y.)|October 26, 2017
A randomized feasibility pilot trial of hearing treatment for reducing cognitive decline: Results from the Aging and Cognitive Health Evaluation in Elders Pilot StudyJennifer A Deal, Marilyn S Albert, Michelle Arnold, et al.
The Oncologist|December 16, 2017
Phase II Study of BEZ235 versus Everolimus in Patients with Mammalian Target of Rapamycin Inhibitor-Naïve Advanced Pancreatic Neuroendocrine TumorsRamon Salazar, Rocio Garcia-Carbonero, Steven K Libutti, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 2, 2013
Randomized multicenter phase II trial comparing two schedules of etirinotecan pegol (NKTR-102) in women with recurrent platinum-resistant/refractory epithelial ovarian cancerIgnace B Vergote, Agustin Garcia, John Micha, et al.
Pageof 7